Fampridine
The question
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the National Institute for Health and Care Excellence on the prescription of Fampridine as a treatment for MS.
Answered by Dr Zubir Ahmed
Ministers and departmental officials have regular discussions with the National Institute for Health and Care Excellence (NICE) on a range of issues, including in relation to its guidelines.
NICE’s guideline on the diagnosis and management of multiple sclerosis in adults, published in June 2022, recommends that fampridine should not be offered to treat mobility issues in people with multiple sclerosis as it is not found to be a cost-effective treatment.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →